Cost regulators for NHS treatments in England and Wales are sticking with their position that Eisai’s Halaven should not be funded by the NHS as a second-line of attack against a certain form of breast cancer.
Read More
Cost regulators for NHS treatments in England and Wales have rejected funding for Eisai’s Halaven as a second-line of attack against a certain form of breast cancer.
Read More
Certain patients with breast cancer may soon be able to get routine access to Eisai’s Halaven on the NHS in England and Wales, after cost regulators endorsed its use.
Read More
